Actively Recruiting

Phase 4
Age: 18Years - 75Years
All Genders
Healthy Volunteers
ID07149792

A Multi-center RCT Clinical Trial on Personalized Precision Medicine for Patients With Psoriasis and Psoriatic Arthritis and Investigation on Cardiovascular Biomarkers

Led by Taichung Veterans General Hospital · Updated on 2025-09-02

50

Participants Needed

2

Research Sites

74 weeks

Total Duration

On this page

Sponsors

T

Taichung Veterans General Hospital

Lead Sponsor

C

Chang Gung Memorial Hospital

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are investigating personalized precision medicine for adults aged 18 to 75 with psoriasis or psoriatic arthritis. This multi-center randomized clinical trial compares a prescreen strategy-based biologics selection using immune cell biomarkers versus standard guideline-based biologics treatment. The study also explores cardiovascular biomarkers to understand disease impact and treatment effects. Participants are randomly assigned to one of two groups: a strategic group where biologics are selected based on individual immune cell screening and biomarker scores, and a standard group receiving biologics per current guidelines without prescreening. Biologics studied include adalimumab, etanercept, certolizumab pegol, golimumab, ustekinumab, secukinumab, ixekizumab, bimekizumab, and brodalumab. Blood samples are cultured to analyze cytokine responses, with follow-up visits scheduled at multiple intervals up to 72 weeks, extending up to 3 years if needed. Participants undergo clinical assessments including Psoriasis Area and Severity Index (PASI), joint counts, Disease Activity in Psoriatic Arthritis (DAPSA) score, Dermatology Life Quality Index (DLQI), and body surface area affected. Cardiovascular health is monitored by measuring internal carotid artery thickness at 6 months, 1 year, and 2 years. Researchers also collect data on pruritus and cytokine levels to evaluate treatment effects. Safety and efficacy outcomes are assessed regularly throughout the study period, with extended follow-up for up to 5 years.

CONDITIONS

Brief Title

A Multi-center RCT Clinical Trial on Personalized Precision Medicine for Patients With Psoriasis and Psoriatic Arthritis and Investigation on Cardiovascular Biomarkers

Who Can Participate

Age: 18Years - 75Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Healthy adults aged 18 to 75 years
  • Diagnosed with psoriasis
  • Diagnosed with psoriatic arthritis
  • Agree to provide a blood sample
Not Eligible

You will not qualify if you...

  • Current history of cancer
  • Recent hospitalization for infection or current antibiotic treatment
  • HIV infection

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 48 weeks

Participants receive biologics treatment. Those in the strategic group undergo prescreening of immune cells with various biologics to select the most appropriate treatment based on biomarker analysis before starting treatment. The standard group receives biologics treatment according to current guidelines without individual immune cell screening.

Clinical assessments at Weeks 0, 2, 4, 12, 24, and 48; intima thickness assessments at Weeks 0 and 48

Follow-up

Duration - Up to 5 years

Participants are followed for extended outcome comparison up to 5 years after treatment to monitor disease activity and quality of life.

Periodic assessments for clinical outcomes

Trial Site Locations

Total: 2 locations

1

Taichung Veterans Hospital

Taichung, Taiwan, Taiwan, 407219

Not Yet Recruiting

2

Taichung Vertenans General Hospital

Taichung, Taiwan, Taiwan, 886

Actively Recruiting

Loading map...

Research Team

J

James Yen, MD PhD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

Phase 1b/2a Open-Label Study to Evaluate Budoprutug (TNT119)...

Immune Thrombocytopenia (ITP)

Actively Recruiting

20 locations

Efficacy of IL-17 Inhibitors on Subclinical Enthesitis in Pa...

Psoriasis (PsO)

Actively Recruiting

2 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here